(a, b) Design of anticoagulant fibers carrying NU172 and RA-36 aptamers with three possible aptamer locations within the fibers being indicated. (c) Binding of anticoagulant fibers to thrombin, ...
Heparin. UFH is one of two agents that comprise conventional anticoagulant therapy. It is considered a natural agent and has been the standard of care for many years. Its mechanism of action is ...
Anticoagulant or antiplatelet drugs, sometimes called blood thinners, help prevent blood clots. There are many options, including heparin and warfarin. Preventing clots reduces the risk of stroke and ...
The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit factor Xa Three NOAC reversal ...
SOUTH SAN FRANCISCO, Calif., PRINCETON, N.J. and NEW YORK, June 22, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (PTLA), Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) today announced ...
Anticoagulant treatments are crucial for managing many conditions, such as heart disease, stroke and venous thrombosis. Current options, however, carry an inherent risk of serious bleeding due to ...
While blood clotting is important to prevent blood loss and for our immunity, coagulation also can cause health issues and even death. Currently, one in four people worldwide dies from diseases and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback